ABERRANT EXPRESSION OF THE C-ERBB-2/NEU PROTOONCOGENE IN OVARIAN-CANCER
ABERRANT EXPRESSION OF THE C-ERBB-2/NEU PROTOONCOGENE IN OVARIAN-CANCER
复制标题
DOI：
10.1016/0304-3835(92)90166-s
复制
发表时间：
1992-01-10
期刊：
影响因子：
9.7
通讯作者：
SHI, DR
中科院分区：
文献类型：
--
作者：
HUNG, MC;ZHANG, X;SHI, DR
最近在美国收集的卵巢肿瘤中发现了c-erbB-2/neu原癌基因的过度表达。众所周知，环境和文化因素可能导致某些类型的癌症，因此，我们通过免疫组织化学染色检测了来自中国的卵巢肿瘤中c-erbB-2/neu的表达。81例肿瘤标本中57例（70.4%）呈免疫阳性，而17例正常卵巢组织标本中仅有1例（5.9%）呈微阳性。我们的研究结果表明，无论在不同人群中，c-erbB-2/neu的过表达是卵巢癌的普遍现象。为了寻找c-erbB/neu过表达细胞系，进一步研究其分子机制，我们还对来自女性生殖道的13株癌细胞进行了c-erbB-2/neu的表达分析。c-erbB-2/neu RNA在四种卵巢癌细胞系中被发现至少过表达100倍。异常的c-erbB-2/neu RNA在该细胞系中也被发现过表达。Southern blot分析表明，c-erbB-2/neu基因扩增2 ~ 4倍，部分等位基因发生结构改变，可能是c-erbB-2/neu基因表达异常的原因。由于2 - 4倍的基因扩增与RNA中bb0 - 100倍的过表达不成比例，因此卵巢癌中该基因的过表达一定涉及转录或转录后控制等其他机制。
Overexpression of the c-erbB-2/neu protooncogene has recently been shown in ovarian tumors collected from the United States. It is known that environmental and cultural factors may contribute to certain types of cancer, therefore, we examined expression of c-erbB-2/neu in ovarian tumors collected from China by immunohistochemical staining. Out of 81 tumor specimens, 57 (70.4%) were found to be immunopositive, whereas only one out of 17 (5.9%) normal ovarian tissue samples was slightly positive. Our results indicate that overexpression of c-erbB-2/neu is a general phenomenon for ovarian cancer regardless of different population. To search for a c-erbB/neu overexpressing cell line for future study on molecular mechanism, we also analyzed 13 cancer cell lines from the female genital tract for expression of c-erbB-2/neu. The c-erbB-2/neu RNA was found to be overexpressed at least 100-fold in one of the four ovarian cancer cell lines examined. An aberrant c-erbB-2/neu RNA was also found to be overexpressed in this cell line. Southern blot analysis indicated that the c-erbB-2/neu was amplified 2 - 4-fold in this line, and some of these alleles have structural alteration which may account for expression of the aberrant c-erbB-2/neu RNA. Since the 2 - 4-fold gene amplification is not proportional to the > 100-fold overexpression in RNA, other mechanisms such as transcriptional or post-transcriptional control must be involved in overexpression of this gene in ovarian cancer.